[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” custom_padding=”||0px|||” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”||30px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n
ClinicalTrials.gov ID:<\/strong> NCT06637631 Official title: <\/strong>A multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 2 dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease.<\/p>\n This is a Phase 2 study that is multinational, multicenter, randomized, double-blind, placebo-controlled, and dose-ranging to investigate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease (CD).<\/p>\n The primary objective of this study is to evaluate the efficacy of different dosages of SAR441566 compared to placebo in participants with moderate to severe Crohn’s disease.<\/p>\n The estimated total duration of the study is up to 59 weeks. This includes: <\/p>\n The main study phase includes a double-blind treatment phase with 12 weeks of induction, followed by 40 weeks of maintenance therapy.<\/p>\n In addition, eligible participants will be offered an open-label treatment phase of up to 40 weeks. The combined duration of the double-blind maintenance phase and the open-label treatment phase must not exceed 40 weeks in total, depending on when the participants switch. <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" A study to investigate the efficacy and safety of SAR441566 in patients with Crohn’s disease (SPECIFI-CD) ClinicalTrials.gov ID: NCT06637631Sponsor: Sanofi (Information provided by Sanofi (responsible party)) Study overview Official title: A multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 2 dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[27],"tags":[],"class_list":["post-452","post","type-post","status-publish","format-standard","hentry","category-beendet"],"yoast_head":"\n
Sponsor:<\/strong> Sanofi (Information provided by Sanofi (responsible party))<\/p>\nStudy overview<\/h3>\n
Brief summary<\/h3>\n
\n